The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...

Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...

The global generic oncology drugs market is projected to grow at a 6% CAGR from 2022 to 2028, reaching over USD 34.8 billion ...

Locally advanced cervical cancer remains a substantial source of mortality, particularly in low-resource settings.1 ...

Artificial intelligence chatbots cannot be relied on to give accurate, safe or even clear advice about medication, according ...

GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

Commenting on the macroeconomic reality and its impact on the industrial sector, the Chartered Institute of Directors (CIoD) ...

Hindustan Unilever Ltd. has filed an appeal with the income tax appellate authority, challenging a demand of over Rs 962.75 ...